FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention refers to compositions and pharmaceutical preparations for treating or preventing central and peripheral nervous system disorders. Composition contains at least one active pharmaceutical ingredient selected from 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide and its pharmaceutically acceptable salts, and at least one excipient which is selected from excipients and binders. Said active pharmaceutical ingredient is present in a granular form. Volumetric density of composition exceeds 0.2 g/ml. Also described is a dosage form selected from tablets and capsules. Methods of preparing the composition and the dosage form are also described.
EFFECT: compositions of the invention containing the granulated said active pharmaceutical ingredient are characterized by high bulk density, compressibility and fluidity.
31 cl, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL FORMULATIONS CONTAINING NITROCATECHOL DERIVATIVES, AND METHODS FOR PREPARING THEM | 2010 |
|
RU2550133C2 |
| SCHEDULE OF NITROCATECHOL INTRODUCTION | 2009 |
|
RU2557532C2 |
| DOSAGE FORMS FOR ORAL APPLICATION CONTAINING LICARBAZEPINE ACETATE | 2008 |
|
RU2546521C2 |
| METHODS OF TREATING GASTROINTESTINAL TRACT DISORDERS INDEPENDENTLY ON FOOD CONSUMPTION | 2014 |
|
RU2563993C1 |
| ORALLY ADMINISTERED PHARMACEUTICAL GRANULE OF EPIDERMAL GROWTH FACTOR | 2011 |
|
RU2540503C2 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| NITROCATECHOL DERIVATIVES AS COMP INHIBITORS | 2006 |
|
RU2441001C2 |
| PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN | 2008 |
|
RU2484816C2 |
| COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2017 |
|
RU2769251C2 |
| COMT INHIBITOR DOSAGE REGIMEN | 2007 |
|
RU2518483C2 |
